(Total Views: 59)
Posted On: 12/02/2024 2:34:11 PM
Post# of 2863

$DYAI Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology https://finance.yahoo.com/news/dyadic-receive...00271.html

